Smithfield Trust Co. trimmed its stake in Bristol-Myers Squibb Co (NYSE:BMY) by 4.3% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 23,756 shares of the biopharmaceutical company’s stock after selling 1,069 shares during the quarter. Smithfield Trust Co.’s holdings in Bristol-Myers Squibb were worth $1,503,000 at the end of the most recent quarter.
Other institutional investors also recently added to or reduced their stakes in the company. Hunter Associates Investment Management LLC lifted its holdings in shares of Bristol-Myers Squibb by 4.4% during the fourth quarter. Hunter Associates Investment Management LLC now owns 18,488 shares of the biopharmaceutical company’s stock valued at $1,133,000 after purchasing an additional 780 shares in the last quarter. Harwood Advisory Group LLC lifted its holdings in shares of Bristol-Myers Squibb by 11.4% during the fourth quarter. Harwood Advisory Group LLC now owns 7,784 shares of the biopharmaceutical company’s stock valued at $476,000 after purchasing an additional 799 shares in the last quarter. Howard Capital Management lifted its holdings in shares of Bristol-Myers Squibb by 0.5% during the fourth quarter. Howard Capital Management now owns 176,010 shares of the biopharmaceutical company’s stock valued at $10,786,000 after purchasing an additional 804 shares in the last quarter. Staley Capital Advisers Inc. lifted its holdings in shares of Bristol-Myers Squibb by 11.7% during the third quarter. Staley Capital Advisers Inc. now owns 7,801 shares of the biopharmaceutical company’s stock valued at $497,000 after purchasing an additional 817 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. lifted its holdings in shares of Bristol-Myers Squibb by 0.8% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 105,519 shares of the biopharmaceutical company’s stock valued at $6,466,000 after purchasing an additional 818 shares in the last quarter. 71.29% of the stock is currently owned by institutional investors and hedge funds.
Bristol-Myers Squibb opened at $52.77 on Friday, Marketbeat Ratings reports. Bristol-Myers Squibb Co has a fifty-two week low of $49.96 and a fifty-two week high of $70.05. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.39 and a current ratio of 1.52. The stock has a market capitalization of $86.12 billion, a price-to-earnings ratio of 17.53, a PEG ratio of 1.32 and a beta of 0.99.
Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, April 26th. The biopharmaceutical company reported $0.94 EPS for the quarter, topping analysts’ consensus estimates of $0.85 by $0.09. The business had revenue of $5.19 billion during the quarter, compared to analysts’ expectations of $5.25 billion. Bristol-Myers Squibb had a return on equity of 37.56% and a net margin of 4.37%. The business’s quarterly revenue was up 5.4% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.84 earnings per share. equities analysts predict that Bristol-Myers Squibb Co will post 3.42 earnings per share for the current year.
The business also recently declared a quarterly dividend, which was paid on Tuesday, May 1st. Shareholders of record on Friday, April 6th were given a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a yield of 3.03%. The ex-dividend date was Thursday, April 5th. Bristol-Myers Squibb’s payout ratio is 53.16%.
A number of research analysts have recently issued reports on BMY shares. Zacks Investment Research downgraded Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a report on Monday, January 29th. Vetr raised Bristol-Myers Squibb from a “sell” rating to a “hold” rating and set a $60.72 price target on the stock in a report on Thursday, February 1st. Leerink Swann upped their price target on Bristol-Myers Squibb from $71.00 to $76.00 and gave the company a “positive” rating in a report on Tuesday, February 6th. BMO Capital Markets lowered their price target on Bristol-Myers Squibb from $52.00 to $51.00 and set an “underperform” rating on the stock in a report on Tuesday, February 6th. Finally, Morgan Stanley raised Bristol-Myers Squibb from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $51.56 to $78.00 in a report on Thursday, February 15th. Three research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and seven have given a buy rating to the company. Bristol-Myers Squibb presently has an average rating of “Hold” and an average price target of $62.84.
In related news, Director Dinesh C. Paliwal purchased 4,770 shares of Bristol-Myers Squibb stock in a transaction on Monday, April 30th. The stock was acquired at an average price of $52.40 per share, for a total transaction of $249,948.00. Following the completion of the transaction, the director now directly owns 8,027 shares in the company, valued at approximately $420,614.80. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 0.23% of the company’s stock.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in the various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.